DK0986644T3 - Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer - Google Patents

Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer

Info

Publication number
DK0986644T3
DK0986644T3 DK98941401T DK98941401T DK0986644T3 DK 0986644 T3 DK0986644 T3 DK 0986644T3 DK 98941401 T DK98941401 T DK 98941401T DK 98941401 T DK98941401 T DK 98941401T DK 0986644 T3 DK0986644 T3 DK 0986644T3
Authority
DK
Denmark
Prior art keywords
epo
erythropoietin
human
preparation
endogenous gene
Prior art date
Application number
DK98941401T
Other languages
Danish (da)
English (en)
Inventor
Anne Stern
Michael Brandt
Konrad Honold
Hans Koll
Johannes Auer
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0986644(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/de
Priority claimed from US09/113,692 external-priority patent/US6548296B1/en
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of DK0986644T3 publication Critical patent/DK0986644T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98941401T 1997-07-23 1998-07-22 Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer DK0986644T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97112640 1997-07-23
DE1997153681 DE19753681A1 (de) 1997-12-03 1997-12-03 Erythropoietin mit hoher spezifischer Aktivität
US09/113,692 US6548296B1 (en) 1997-07-23 1998-07-10 Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PCT/EP1998/004590 WO1999005268A1 (de) 1997-07-23 1998-07-22 Herstellung von erythropoietin durch endogene genaktivierung

Publications (1)

Publication Number Publication Date
DK0986644T3 true DK0986644T3 (da) 2007-01-29

Family

ID=27217987

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98941401T DK0986644T3 (da) 1997-07-23 1998-07-22 Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer

Country Status (13)

Country Link
EP (1) EP0986644B1 (pt)
JP (1) JP4541539B2 (pt)
CN (1) CN1151258C (pt)
AT (1) ATE341625T1 (pt)
AU (1) AU754619B2 (pt)
BR (1) BRPI9811031B8 (pt)
CA (1) CA2298015C (pt)
DE (1) DE59813758D1 (pt)
DK (1) DK0986644T3 (pt)
ES (1) ES2273434T3 (pt)
TR (1) TR200000175T2 (pt)
TW (1) TW574372B (pt)
WO (1) WO1999005268A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP4220125B2 (ja) 1997-12-03 2009-02-04 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 高い比活性を有するエリスロポエチン
WO2003048348A2 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
WO2002064085A2 (en) 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
KR100493703B1 (ko) * 2001-10-30 2005-06-02 신풍제약주식회사 동물세포용 재조합 벡터 및 에리트로포이에틴을 대량으로 생산하기 위한 동물세포용 발현벡터
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
BR0214557A (pt) 2001-11-28 2006-06-06 Ortho Mcneil Pharm Inc regime de dosagem de eritropoietina para o tratamento de anemia
US7129267B2 (en) 2002-03-11 2006-10-31 Janssen Pharmaceutica N.V. Methods for SHP1 mediated neuroprotection
EP1520008B1 (en) 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
EA008670B1 (ru) 2003-05-09 2007-06-29 Круселл Холланд Б.В. Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
EP2134862A4 (en) * 2007-03-12 2011-04-20 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETIC MICROVASCULAR COMPLICATIONS
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
EP2334699B1 (en) * 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
CN104059128B (zh) * 2010-09-17 2016-08-03 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN102659928B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN102659927B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
JPS62171696A (ja) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
JPS62265992A (ja) * 1986-05-12 1987-11-18 Ajinomoto Co Inc ヒト細胞を用いる有用物質の製造方法
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
JPH01165393A (ja) * 1987-12-21 1989-06-29 Sumitomo Chem Co Ltd 組換えヒトエリスロポエチンの精製方法
EP0747485B1 (en) * 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
ES2151463T5 (es) * 1989-12-22 2012-10-29 Merck Serono Sa Constructos de ADN para la activación y la modificación de la expresión de genes endógenos
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
CA2298015A1 (en) 1999-02-04
JP2001511343A (ja) 2001-08-14
TR200000175T2 (tr) 2001-01-22
DE59813758D1 (de) 2006-11-16
BRPI9811031A (pt) 2000-08-08
BRPI9811031B1 (pt) 2011-10-04
AU754619B2 (en) 2002-11-21
CN1151258C (zh) 2004-05-26
BRPI9811031B8 (pt) 2021-07-06
JP4541539B2 (ja) 2010-09-08
CN1265143A (zh) 2000-08-30
TW574372B (en) 2004-02-01
ES2273434T3 (es) 2007-05-01
ATE341625T1 (de) 2006-10-15
EP0986644B1 (de) 2006-10-04
EP0986644A1 (de) 2000-03-22
WO1999005268A1 (de) 1999-02-04
CA2298015C (en) 2015-01-27
AU8978698A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
DK0986644T3 (da) Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer
WO2002029083A3 (en) Industrial-scale serum-free production of recombinant proteins in mammalian cells
PT1428878E (pt) Processo para a produção e purificação de eritropoietina
BR0010806A (pt) Métodos e materiais para a sìntese de produtos orgânicos
EP0931162A4 (en) PRODUCTION OF A MULTIMERAL PROTEIN BY CELL FUSION PROCESS
CY1111099T1 (el) Στελεχη ζυμης τα οποια παραγουν στεροειδη με αυτονομο τροπο
MY134696A (en) Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
EP1095158A4 (en) METHOD AND MATERIALS FOR THE PRODUCTION OF GLUCOSAMINE
DE69635675D1 (de) Verkürzter aus einer gliazelllinie gewonnener neurotropher faktor
EP0367145A3 (en) New process for the production of l-2-amino-4(hydroxymethyl-phospinyl)-butyric acid
ATE437951T1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
DK1015494T3 (da) Fremgangsmåde til fremstilling af katalytiske antistoffer
DK1346026T3 (da) Mikroorganisme, der producerer 5'inosinsyre, og fremgangsmåde til produktion af 5'inosinsyre under anvendelse af denne
NO993119L (no) Materiale som inneholder polyreaksjonsprodukter og fremgangsmåte for fremstilling av samme
DE69931807D1 (de) Herstellung von ascorbinsäure unter verwendung von hefe
DK1000154T3 (da) Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
CA2412049A1 (en) Process for the preparation of 5-aminosalicyclic acid
ATE413451T1 (de) Methoden zur massenkultivierung von zellen die rekombinantes menschliches erythropoietin produzieren
DK1019512T3 (da) Fremgangsmåde til fremstilling af forgrenede fedtsyrer ved hjælp af genetisk modificerede planter
DK1001929T3 (da) Fremgangsmåde til fremstilling af 3-cyano-2,4-dihalogen-5-flour-benzoesyrer
HUT50099A (en) Process for producing alkyl-esters of 4-chloro-3-alkoxy-but-2e-enic acid
AU5497396A (en) Process for the synthesis of nucleoside analogues
WO1999051722A3 (de) Rekombinante l-n-carbamoylase aus arthrobacter aurescens, verfahren zur herstellung von l-aminosäuren mittels dieser
TR200700154A2 (tr) Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
WO2001090339A3 (en) Methods and compositions to activate genes in cells